Deming's Longevity Fund was at its founding somewhat ahead of the times, as it should given that she put in time at the SENS Research Foundation and related gro

Deming's Longevity Fund was at its founding somewhat ahead of the times, as it should given that she put in time at the SENS Research Foundation and related groups back in the day. The rest of the venture community is beginning to wake up now - if even I, with my limited connections, am aware of a couple of groups raising new venture funds to target the biotechnologies of longevity, then I'm sure there are a bunch more I don't know about. Expect to see a crop of companies working with the biochemistry of aging over the next few years now that deep pockets like Google, Abbvie, and the Human Longevity backers have expressed their interest with dollars. That sets up all the right signals for acquirers and other liquidity events. Sadly I imagine that most of these companies will be garbage - either a waste of everyone's time like Elysium or a clever way of getting for-profit investors to pay for fundamental research that goes nowhere other than knowledge generation, like Sirtris. Still, there are gems in there for those who understand the science well enough to identify high expectation value lines of research. Oisin Biotechnologies, for example, and perhaps UNITY Biotech if they choose a good therapy. Both are aiming to clear senescent cells, which has a lot of backing as an approach.